In recent years, immunotherapy has emerged as a promising therapeutic avenue for various cancers, with monoclonal antibodies targeting immune checkpoints, such as PD‐1 and CTLA‐4, demonstrating clinical efficacy across diverse tumor types. This evidence concerns the gene CTLA4 and neoplasm.